Key result
Incident AF is linked to up to ~1.8 mm Hg higher visit-to-visit systolic BP variability.
Why the study?
The association between blood pressure variability and atrial fibrillation in hypertensive patients with high cardiovascular risk was not well understood.
Is atrial fibrillation associated with increased blood pressure variability in hypertensive patients with high cardiovascular risk?
Observational (n=13,827)
Is atrial fibrillation associated with increased blood pressure variability in hypertensive patients with high cardiovascular risk?
Effect estimate: mean difference 1.2 and 1.8 mm Hg
p-value: p=<0.0001
Incident atrial fibrillation, but not baseline atrial fibrillation, is associated with increased visit-to-visit blood pressure variability in high-risk hypertensive patients.
Incident AF signals higher visit-to-visit BP variability in high-risk hypertension; leaves open causality and whether targeting variability alters outcomes.
PURPOSE: Blood pressure variability is associated with traditional cardiovascular risk factors, but little is known about the association with atrial fibrillation. We compared blood pressure variability in patients with and without atrial fibrillation using data from the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. MATERIALS AND METHODS: The VALUE trial was a randomised-controlled trial of valsartan versus amlodipine in patients with hypertension and high cardiovascular risk, followed for 4.2 years (mean). For the present analysis we included patients with electrocardiogram at baseline and during follow-up, and ≥3 visits from 6 months onwards. We compared standard deviation (SD) of all blood pressures within each visit averaged across all visits (within-visit variability) and of mean blood pressure at each visit (visit-to-visit variability) in patients with and without atrial fibrillation at baseline. We similarly compared patients who developed non-persistent or persistent atrial fibrillation during follow-up with those who did not, using t-tests, ANOVA and linear regression. RESULTS: Of 15,245 patients in the VALUE trial, 13,827 were eligible for analysis. SD of visit-to-visit systolic blood pressure was not significantly different between patients with and without atrial fibrillation at baseline (mean difference 0.3 mm Hg, p = 0.4), but significantly higher in patients with incident non-persistent or persistent atrial fibrillation during follow-up than in those who never developed atrial fibrillation (differences 1.2 and 1.8 mm Hg, respectively, p-values <0.0001). Associations with non-persistent and persistent atrial fibrillation were confirmed in linear regression models (p-values <0.0001). SD of within-visit systolic blood pressure was not significantly different between patients with and without atrial fibrillation at baseline (p = 0.4) but significantly higher in patients with persistent atrial fibrillation during follow-up (p = 0.04). CONCLUSION: In patients treated for hypertension, atrial fibrillation was not associated with increased blood pressure variability, but blood pressure variability was higher in those who developed atrial fibrillation during follow-up.
No takes yet. Share an insight, caveat, or question.
Mehlum et al. (2019) conducted an observational in Hypertension and high cardiovascular risk (n=13,827). Atrial fibrillation vs. No atrial fibrillation was evaluated on Standard deviation of visit-to-visit systolic blood pressure (mean difference 1.2 and 1.8 mm Hg, p=<0.0001). Incident non-persistent and persistent atrial fibrillation were associated with higher visit-to-visit systolic blood pressure variability (mean differences 1.2 and 1.8 mm Hg, P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: